Quoting MedicalNewsToday:
“..The antibody, known as anti-CD25 mAb dacluzimab, targets T regulatory cells (Tregs), naturally occurring cells which tumors harness to dampen the body’s normal immune response….Penn Medicine team’s approach uses the antibody to turn off the Treg cells’ function in the immune system and boosting the effectiveness of a telomerase/survivin peptide vaccine made to tackle the cancer…”

This is a study on a small group. so obviously more data is needed. But when one has advanced metastasized cancer, what really should matter is choosing the right “silver bullet’.        medicalnewstoday

Leave a Reply

Your email address will not be published. Required fields are marked *

Current month ye@r day *

© 2013-2019 Medical News Digest All Rights Reserved